Molecular Formula | C17H12Cl2N2O6S |
Molar Mass | 443.26 |
Density | 1.619±0.06 g/cm3(Predicted) |
Boling Point | 663.2±55.0 °C(Predicted) |
pKa | 12.33±0.30(Predicted) |
Storage Condition | 2-8°C,密封,干燥 |
In vitro study | In PDE4 assays Lirimilast (BAY 19-8004) is reported to be 5-fold more potent than Cilomilast and equipotent with CDP-840 using freshly prepared PDE4 from human PMNL. |
In vivo study | Since Lirimilast (BAY 19-8004) is orally active in the guinea-pig at 3 mg/kg and, more critically, in primates at 0.1 mg/kg/day it appears to have a good therapeutic ratio. In addition Lirimilast is found to be 3-fold more potent than Cilomilast when compared in a rat model of lung neutrophilic inflammation. |
biological activity | Lirimilast (BAY 19-8004) is a potent, A selective and orally active phosphodiesterase 4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used in the study of asthma or chronic obstructive pulmonary disease (COPD) with potent anti-inflammatory properties. |